Pyruvate kinase M2 links metabolic reprogramming and inflammatory signaling in autoimmune diseases

Pyruvate kinase M2 (PKM2) is a glycolytic enzyme that also exerts non-metabolic functions in transcriptional regulation and represents an emerging pharmacological target in inflammation-related disorders. Emerging evidence indicates that altered PKM2 expression, conformational switching and nuclear translocation contribute to the pathogenesis of autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes and its complications, systemic sclerosis, psoriasis, systemic lupus erythematosus and multiple sclerosis. In the cytoplasm, PKM2 regulates glycolytic flux and supports the metabolic demands of activated immune cells and disease-relevant parenchymal or fibroblast-like cells. Under inflammatory, hypoxic or growth factor-related stimulation, dimeric PKM2 translocates into the nucleus and cooperates with HIF-1α, STAT3, β-catenin and BCL6 to amplify inflammatory, fibrotic and tissue-remodeling programs. Pharmacological strategies that modulate PKM2, particularly by promoting tetramerization, altering enzymatic activity or limiting nuclear translocation, have shown therapeutic potential in preclinical models. However, PKM2 functions differ across cell types and disease contexts, including protective roles in epithelial repair and diabetic nephropathy. Therefore, PKM2-targeted strategies should move beyond global inhibition toward selective and context-dependent modulation of conformation, enzymatic activity and nuclear trafficking. Defining these divergent functions may provide a mechanistic and pharmacological basis for more selective immunometabolic therapies in autoimmune diseases.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.3389/fphar.2026.1995943
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pyruvate kinase M2 links metabolic reprogramming and inflammatory signaling in autoimmune diseases

Qingmiao Zhu, Ting Zhao, Yingxin Kang, Zhuchen Tan et al.
1 links
Frontiers in Pharmacology
Cancer, Hypoxia, and Metabolism
article

Pyruvate kinase M2 links metabolic reprogramming and inflammatory signaling in autoimmune diseases

Qingmiao Zhu, Ting Zhao, Yingxin Kang, Zhuchen Tan, Xiaolong Li, Huimin Xu, Yongsheng Fan, Chengping Wen
article en

Abstract

Pyruvate kinase M2 (PKM2) is a glycolytic enzyme that also exerts non-metabolic functions in transcriptional regulation and represents an emerging pharmacological target in inflammation-related disorders. Emerging evidence indicates that altered PKM2 expression, conformational switching and nuclear translocation contribute to the pathogenesis of autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes and its complications, systemic sclerosis, psoriasis, systemic lupus erythematosus and multiple sclerosis. In the cytoplasm, PKM2 regulates glycolytic flux and supports the metabolic demands of activated immune cells and disease-relevant parenchymal or fibroblast-like cells. Under inflammatory, hypoxic or growth factor-related stimulation, dimeric PKM2 translocates into the nucleus and cooperates with HIF-1α, STAT3, β-catenin and BCL6 to amplify inflammatory, fibrotic and tissue-remodeling programs. Pharmacological strategies that modulate PKM2, particularly by promoting tetramerization, altering enzymatic activity or limiting nuclear translocation, have shown therapeutic potential in preclinical models. However, PKM2 functions differ across cell types and disease contexts, including protective roles in epithelial repair and diabetic nephropathy. Therefore, PKM2-targeted strategies should move beyond global inhibition toward selective and context-dependent modulation of conformation, enzymatic activity and nuclear trafficking. Defining these divergent functions may provide a mechanistic and pharmacological basis for more selective immunometabolic therapies in autoimmune diseases.

Frontiers in PharmacologyVol. 17
Zhejiang Chinese Medical University (CN)
Zhejiang Chinese Medical University, Natural Science Foundation of Zhejiang Province
Good health and well-being
Cancer, Hypoxia, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon